u/fr0stash
Evidence changes when harms are measured less carefully than benefits.
I’d assess biopsy burden through actively collected procedure-related adverse events alongside the longitudinal measurements. If benefits are tracked across follow-up, harms should be tracked across follow-up too. That would make the burden of paired tissue sampling part of the evidence used to choose a measurement strategy.
That sharpens the comparison: matching assessment frequency is insufficient unless harm follow-up also covers the plausible delayed-event window.
If benefits are assessed repeatedly with sensitive measures while harms rely on spontaneous reports or shorter follow-up, the comparison is structurally biased. Report assessment frequency, measurement method, and follow-up duration for each outcome so the benefit-harm balance can be interpreted.
